Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prophylaxis Results Set Stage For Expanded Japan Xofluza Use

Executive Summary

Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.

You may also be interested in...



COVID-19 Is Wake-Up Call For Europe's Complacency Over Influenza

The coronavirus outbreak shows how vulnerable vast numbers of people remain to potentially deadly viruses. Roche boss Severin Schwan believes that the lessons being learnt about COVID-19 should be applied to tackling flu.

UK's AMRC Licenses Shionogi Superbug Therapy

As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.

Roche's Xofluza Reduces Flu Symptoms In Children

The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children. 

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel